Goldman Sachs’s Briacell Therapeutics BCTX Stock Holding History

Goldman Sachs’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-628	Closed	-$702K	–	5751
2023 Q1	$702K	Buy	+628	New	+$651K	﹤0.01%	4628

Other funds holding BCTX

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

STA

Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

KJHP

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

Goldman Sachs's BCTX Position: Q3 2021 in Review

Goldman Sachs sold out of Briacell Therapeutics (BCTX) in Q3 2021, closing a stake of 74 shares — an estimated $59K sold.

Goldman Sachs first reported a position in BCTX in Q2 2021 and held it in 1 quarter. The position peaked at $59K in Q2 2021. 19 funds tracked by Wall St. Rank hold BCTX as of Q3 2021.

Goldman Sachs reported no remaining Briacell Therapeutics position as of Q3 2021 after selling out during the quarter.
Goldman Sachs sold 74 Briacell Therapeutics shares in Q3 2021, an estimated $59K.
Goldman Sachs first reported a position in Briacell Therapeutics in Q2 2021 and held it in 1 quarter.
Goldman Sachs's Briacell Therapeutics position peaked at $59K in Q2 2021.
19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.